Test Price
2,800 AED✅ Home Collection Available
GHR Gene Analysis (Growth Hormone Insensitivity, Partial) – Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Assurance: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.
- Premium Home Collection: VIP mobile phlebotomy with hospital-grade cold-chain transport, available daily from 8 AM to 11 PM.
- Post-Test Clinical Guidance: Complimentary phone session with our genetic counsellor to interpret results.
- Insurance: Direct coverage verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test analyzes the entire coding region of the GHR gene to identify pathogenic variants linked to partial growth hormone insensitivity (Laron syndrome). The assay empowers early diagnosis, customized management, and genetic counselling for families in the UAE.
| Feature | Our Test (NGS Panel) | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity – full exon coverage | Sanger sequencing of common hotspots only (75–85% pick-up) |
| Methodology | NGS with copy number analysis (CNV) | Conventional PCR + Sanger (no CNV detection) |
| Turnaround Time | 3 to 4 weeks | 6 to 8 weeks |
Physician Insight & Safety Protocols
“This genomic test provides critical insights into partial growth hormone insensitivity, revealing GHR variants that may explain short stature despite normal GH levels. As a clinical geneticist, I emphasize that genetic results must be interpreted alongside clinical and biochemical findings for accurate diagnosis. Your child’s growth trajectory remains our priority—please share this report with your endocrinologist for a comprehensive care plan.” — Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA License: 9294403)
Advisory Notice
⚠️ Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Growth hormone therapy adjustments should only be made under specialist supervision after genetic results are clinically correlated.
Exclusion Criteria & ER Red Flags
- Exclusion: Active bleeding disorder or severe anaemia that precludes safe venipuncture. Neonatal microsampling may be performed with a clinician’s approval.
- Exclusion: Inability to provide informed consent by a legal guardian (essential for minors per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Red Flag – Seek Emergency Care: Sudden lethargy, hypoglycaemic seizures, or loss of consciousness in a child with known growth failure; may signal a metabolic crisis requiring immediate intervention.
- Red Flag: Profound electrolyte disturbances or respiratory distress in a newborn—consider urgent endocrine evaluation.
All sample handling follows UAE data privacy regulations and clinical safety standards.
Patient FAQ & Clinical Guidance
1. What does this test detect, and who should consider it?
Direct Answer: This test detects DNA sequence variants in the GHR gene that cause partial growth hormone insensitivity, leading to short stature and metabolic abnormalities even when GH levels are normal. It is recommended for children with unexplained short stature, delayed growth, or a family history of Laron syndrome, under the guidance of a paediatric endocrinologist.
2. How is the sample collected, and is it painful?
Direct Answer: Our DHA-licensed phlebotomist performs a gentle blood draw or a simple finger-prick onto an FTA card during your home visit, ensuring minimal discomfort and strict cold-chain transport. VIP mobile phlebotomy is available daily from 8 AM to 11 PM.
3. When will I receive my results, and what support is provided?
Direct Answer: Results are typically delivered within 3 to 4 weeks, accompanied by a post-test clinical guidance session with our genetic counsellor to help you interpret the findings and discuss next steps with your physician.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
DNA Labs UAE operates under DHA Facility License No. 1143 and strictly adheres to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensures patient data confidentiality.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs digital health data handling.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – governs clinical testing safety and patient consent.
All genetic data is encrypted, access-controlled, and processed exclusively within UAE servers. Your privacy is our priority.
Clinical & Logistical Metadata
| Test Name | GHR Gene Analysis (Growth Hormone Insensitivity, Partial) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube) or FTA card |
| Methodology Used | Next Generation Sequencing (NGS) with CNV analysis |
| ICD-10-CM Code | E34.3 (Short stature due to endocrine disorder), E23.0 (Hypopituitarism) – differential |
| LOINC Code | 21662-6 (GHR gene mutation analysis) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians